Emma Andrus, Editor

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Eichenfield discusses safety, lab monitoring, and treatment positioning of icotrokinra in adolescents with moderate to severe plaque psoriasis.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

New prospective data from the DECIDE study reinforce the role of the 31-GEP test in clinical decision-making.

Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Pelthos and Channel Therapeutics will merge to form a new publicly traded entity focused on commercializing the first at-home treatment for molluscum.

Eichenfield discusses high skin clearance and safety in teens with psoriasis, per new ICONIC-LEAD phase 3 data.

This review of the latest dermatologic studies includes insights into dermatologic associations in patients with Crohn disease, the prevalence of tinea pedis in pediatric populations, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Evommune has initiated a global phase 2b trial of EVO756, a first-in-class MRGPRX2 antagonist, for moderate to severe CSU.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Interim FDA-funded study results show HyBryte delivers rapid, sustained response and strong safety in early-stage CTCL patients.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Subcutaneous methotrexate may offer improved efficacy and patient adherence in psoriasis treatment, though it comes at a higher cost.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Henry Lim, MD, discusses the ILDS’ renewed WHO relations status and the global crisis of corticosteroid misuse in skin-bleaching products.

A new subgroup analysis revealed higher rates of clear or almost clear skin at week 16 vs placebo with a favorable safety profile.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

The study revealed high disease burden, poor quality of life, and need for more effective, targeted treatments.

Raj Chovatiya, MD, PhD, MSCI, explores case-based approaches to managing atopic dermatitis, focusing on treatment strategies, challenges, and clinical insights for improving patient outcomes.

This review of the latest dermatologic studies includes insights into disparities in pediatric atopic dermatitis, nurse-led models for skin cancer detection, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

The Kesty Redness Scale offers a validated, easy-to-use tool to reliably assess facial redness in clinical dermatology.

Alphyn Biologics has dosed the first patient in a global phase 2b trial of zabalafin hydrogel for mild to moderate atopic dermatitis.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Long-pulsed KTP laser showed promise as a safe, effective alternative to PDL for treating port-wine birthmarks over 3 years.

Tofacitinib showed promise for easing itch and skin symptoms in prurigo nodularis, though effects may lessen over time.